Last updated: May 22, 2026
Executive summary: Ultravate is a topical corticosteroid (alclometasone dipropionate) with a long commercial history and a mature competitive landscape. Current, decision-grade patent and regulatory market-risk mapping depends on the specific NDA/ANDA identifiers and Orange Book listings for each marketed strength/dosage form (cream vs ointment), plus confirmed trial activity tied to the exact brand or any updated formulations. Without those identifiers and the underlying trial registry records for “Ultravate,” a complete accuracy-grade clinical update and exclusivity-driven launch projection cannot be produced.
H1: Ultravate (alclometasone dipropionate) clinical trials update, market analysis, and market projection
What clinical trials are active for Ultravate (alclometasone dipropionate) in 2026?
Featured snippet answer: A decision-grade “active trials” update requires matching Ultravate to specific registry entries (NCT numbers) and the exact formulation (cream vs ointment) and indication.
How to interpret Ultravate trial signals
- Trial types relevant to topical corticosteroids:
- bioequivalence-style studies for generic intraclass comparators
- vehicle/vehicle-ingredient tolerability and skin irritation endpoints
- pediatric endpoints for safety and efficacy consistency
- flare-control maintenance comparisons in dermatology guidance contexts
- Decision relevance:
- trial activity tied to new formulation patents typically precedes ANDA submissions
- trial activity tied to expanded labeling can shift payer coverage and utilization
Endpoints that drive formulary adoption
- Investigator Global Assessment style outcomes
- Lesion clearance and time-to-improvement
- Safety: skin atrophy signals, HPA-axis suppression screening where indicated, local tolerability
Which indications does Ultravate target and how does that shape utilization?
Featured snippet answer: Ultravate is positioned for inflammatory dermatoses responsive to topical corticosteroids; utilization depends on coverage tiers, steroid potency class, and guideline alignment.
Payer and guideline placement
- Topical corticosteroid selection is typically driven by:
- disease severity and anatomic site
- pediatric suitability
- risk tolerance (atrophy risk, eyelid use restrictions, occlusion guidance)
Site-of-use dynamics for topical steroids
- Face and intertriginous areas increase sensitivity to potency and tolerability, affecting:
- prescriber preference
- insurance prior authorization thresholds
- substitution patterns with mid-potency alternatives
What is Ultravate’s Orange Book status and exclusivity timeline?
Featured snippet answer: A reliable exclusivity and generic entry risk profile requires Orange Book drug product identifiers (NDC-to-listed patent mapping) for the specific Ultravate products.
What typically matters for topical corticosteroids
- Listed patents commonly fall into:
- composition claims (alclometasone dipropionate formulations)
- method-of-use claims (if any)
- formulation/particle or vehicle-specific claims
- manufacturing method or stability-related claims
How exclusivity affects ANDA timing
- 180-day exclusivity hinges on first-filer status and Paragraph IV litigation outcome.
- If formulation patents exist, dermatology-focused generics often launch “at-risk” for specific strengths/vehicles first, then expand.
When does Ultravate lose exclusivity for each marketed strength and dosage form?
Featured snippet answer: Exact dates require product-specific Orange Book parsing (cream vs ointment), including listed patent expirations and any pediatric exclusivity extensions.
Launch scenario structure
- Scenario A: composition patent expiry first
- Scenario B: formulation patent expiry first, forcing generic to match vehicle specs
- Scenario C: method-of-use label restrictions delay “fully substitutable” launches
How many patents protect Ultravate and how strong is the patent estate?
Featured snippet answer: The count and strength cannot be stated accurately without the Orange Book patent list for each Ultravate product.
Patent strength signals used in practice
- Claim scope breadth (composition vs narrow vehicle/process)
- Remaining term at present date
- Stated litigation status per listed patent
- Claim dependency chains that can preserve narrow infringement theories even after some design-arounds
Which generic or biosimilar companies are competing with Ultravate and what entry risks exist?
Featured snippet answer: Generic competition for a mature topical steroid is typically driven by ANDA filings rather than biosimilars. A competitor list requires ANDA-to-product mapping and approval status for each dosage form.
Typical competitor behavior
- Intraclass substitutions at pharmacy counter
- Pharmacy switch programs driven by:
- WAC and rebate dynamics
- PA policies favoring specific molecules or specific strengths
What “at-risk” means for topical steroids
- If a generic matches the formulation claims, risk is lower.
- If the generic uses a different vehicle, risk turns on:
- claim language (vehicle-independent composition vs vehicle-dependent claims)
- court constructions of “effective amount” and “stable” formulation properties
What Ultravate patent litigation affects generic entry (Paragraph IV, settlements, injunctions)?
Featured snippet answer: A litigation-driven market projection requires case dockets tied to Ultravate’s listed patents and the brand’s NDA/Orange Book reference.
What to map from court dockets
- Filed Paragraph IV certifications
- Hearing dates and Markman outcomes
- Settlement triggers:
- “no launch until” dates
- “carve-out” launches for specific strengths
- exclusivity transfers and scope limitations
How litigation outcomes change revenue exposure
- Injunction or stay of approval can delay entry but does not prevent “pipeline launches” of non-infringing variants
- Settlements can lock the market with defined launch corridors
What formulations are protected for Ultravate (cream vs ointment) and what are the manufacturing/IP barriers?
Featured snippet answer: Formulation protection must be tied to the specific listed patents for each product configuration.
Vehicle-driven substitution barriers
- Common reformulation levers:
- differing ointment bases
- emulsions and cream rheology adjustments
- stabilizer and preservative selection
- Key legal question:
- are the claims tied to vehicle composition, particle characteristics, or manufacturing process steps?
How does Ultravate compare with competing topical corticosteroids on market access and substitution?
Featured snippet answer: Competitive substitution depends on potency equivalence, guideline position, and payer preference for specific molecules.
Competitive replacement pathways
- Within-class switching:
- to other medium/low potency corticosteroids based on body site
- Cost-driven switching:
- WAC and rebate structure favors lowest net cost products
- Safety-driven switching:
- patients with prior atrophy or sensitive sites move to lower-risk options
What is the FDA regulatory pathway for Ultravate, and does it affect generic entry?
Featured snippet answer: Regulatory pathway mapping requires the NDA reference and any subsequent supplements for Ultravate’s current marketed label.
Generic pathway mechanics
- ANDA approvals generally rely on:
- pharmaceutic equivalence
- bioequivalence (often waived for topical products depending on system-level criteria)
- safety/label parity requirements
Labeling and interchangeability
- Even with therapeutic equivalence, payers can restrict coverage by:
- age restrictions
- indication specificity
- prior authorization rules tied to steroid potency class
Market analysis: current demand drivers and commercial outlook for Ultravate
Featured snippet answer: As a mature topical corticosteroid, Ultravate’s near-term performance typically depends on:
- generic penetration depth by dosage form,
- payer formulary placement,
- and adverse-event and tolerability perceptions that affect prescriber behavior.
Demand drivers for topical corticosteroids
- Seasonal and region-driven flare patterns
- Dermatology volume trends (atopic dermatitis proxies)
- Retail channel and PBM contract renewal cycles
Revenue exposure mapping logic (what to model)
- Penetration by dosage form (cream vs ointment)
- Net price erosion from generic competition
- Share shift caused by payer “preferred steroid” rules
Market projection: what happens to Ultravate sales under typical generic entry timelines?
Featured snippet answer: A correct projection requires launch timing for each strength/vehicle and the assumed competitive set. Without the Orange Book and ANDA approval/paragraph IV status, the projection cannot be stated accurately.
Three projection templates used in underwriting
- Template 1: limited generic entry (one vehicle first)
- slower share loss, partial price compression
- Template 2: broad ANDA entry at multiple strengths
- steep decline, rapid net sales compression
- Template 3: label or formulation constraints
- delayed substitution, longer “effective monopoly” on interchangeability
What you would quantify once linked to product IDs
- Year-by-year market share dilution assumptions
- Expected net price vs WAC discount rates for the molecule
- Retail vs institutional channel share differences
Key takeaways
- A decision-grade clinical trials update and market projection for “Ultravate” cannot be completed without product-specific identifiers that tie Ultravate’s exact cream/ointment configuration to Orange Book listings and registry trial entries.
- Generic entry risk for topical corticosteroids is dominated by ANDA and formulation/patent scope, not biologics pathways.
- Market projections hinge on (1) strength/vehicle-specific approval timing and (2) whether substitution is blocked by formulation or method-of-use claim scopes.
FAQs
- What is the Orange Book listing for Ultravate cream versus ointment and what patents expire first?
- Are there any active NCT trials for alclometasone dipropionate topical products in atopic dermatitis or other inflammatory dermatoses?
- Which generic ANDAs are approved for Ultravate strengths and what are their substitution limitations, if any?
- Did any Ultravate patents face Paragraph IV challenges, and what settlement dates control generic launch?
- How do topical corticosteroid potency class differences affect payer formulary placement relative to Ultravate?
References
(No cited sources provided.)
